On Monday, Merge Healthcare Inc. (NASDAQ:MRGE)’s shares declined -15.56% to $5.10.
Merge Healthcare Inc. (MRGE) declared the launch of a new business unit, iConnect Network Services, to deliver interoperability services to healthcare enterprises seeking to reduce the labor and overhead costs associated with preceding-authorization processes, improve physician engagement among provider communities, and boost referral success. In an age of consolidation, accountable care, and narrow networks, health systems must have a better handle on the appropriateness and efficiency of the most valuable referrals in their network.
Merge Healthcare Incorporated develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians worldwide.
ImmunoGen, Inc. (NASDAQ:IMGN)’s shares dropped -11.04% to $8.86.
ImmunoGen, Inc. (IMGN) stated financial results for the three-month period ended March 31, 2015 – the third quarter of the Company’s 2015 fiscal year. ImmunoGen also offered an update on its product pipeline and financial guidance.
Daniel Junius, President and CEO stated that they are executing against their product development plan and recently strengthened their financial resources to support these programs. The clinical findings with mirvetuximab soravtansine to date are encouraging, and they look forward to their presentation at ASCO next month. Based on these data and the medical need, they are expanding the compound’s clinical program and implementing preparations to support an accelerated development pathway.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
At the end of Monday’s trade, Neonode, Inc (NASDAQ:NEON)‘s shares dipped -10.96% to $4.06.
Neonode, Inc (NEON) declared that it will release financial results for the quarter ended March 31, 2015 on Wednesday May 6, 2015.
The Company will host a conference call Wednesday May 6, 2015 at 10AM Eastern Daylight Time (EDT) featuring remarks by and Q&A with, Thomas Eriksson, CEO, Lars Lindqvist, CFO and David Brunton, Head of Investor Relations.
Neonode Inc., together with its auxiliaries, develops and licenses user interfaces and optical infrared touch technology solutions in the United States, Japan, China, Taiwan, South Korea, Italy, Sweden, and internationally.
Juno Therapeutics Inc (NASDAQ:JUNO), ended its Monday’s trading session with -10.32% loss, and closed at $50.81.
MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics Inc (JUNO) declared that they have reached a new partnershipto conduct combination clinical trials in immuno-oncology with one of Juno’s investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune’s investigational programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor, MEDI4736. Under the initial development plan, both companies will explore the safety, tolerability and preliminary efficacy of the c
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
